Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: Doug Meetmer who wrote (318)	5/12/1998 5:31:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 717

Doug, Correct. PCYC hasn't discovered a "cure for cancer" - all they have is some promising drugs that are further along than are ENMD's. A couple of minor corrections: In addition, there are numerous other studies underway for their radiation sensitizer in many cancers. To my knowledge, none of these studies (other than the ongoing brain study) has yet started. NCI has agreed to fund 9 Gd-Tex trials in various indications, but these haven't started yet. By all accounts, NCI trials are typically glacial. Also, I want to point out that if Lu-Tex turns out to work for peripheral vascular disease, this stock will be a five bagger overnight. As far as I know, they haven't yet started trials for this indication, however. Phase I trials at Stanford actually started a few months ago. One analyst says these are very much safety trials, with no efficacy data to be expected; I don't know if he's correct on this. Trying to predict PCYC's stock price in this environment is difficult - if the momentum guys get into the game we're going to see a roller coaster. Unless overvaluation gets extreme, I intend to hold for the long run. Peter